Original ArticleSubcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness: A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study
Under an Elsevier user license
open archive
Key Words
Constipation
opioid-induced
methylnaltrexone
peripheral opioid antagonist
subcutaneous
gastrointestinal side effects
advanced illness
clinical trial
dose-ranging
Cited by (0)
This study was sponsored by Progenics Pharmaceuticals, Inc.
Copyright © 2008 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.